The study assessed 20 healthy adult volunteers, administering MRX1 twice daily at levels of 2.5 mg/kg and 7.5 mg/kg. Participants showed no moderate or severe adverse events, and no individuals withdrew from the trial due to complications. Crucially, the data showed no significant shifts in laboratory parameters, including liver function, aligning the drug's performance with established standards for approved CBD therapies.
Ananda Pharma Clears Phase 1 Hurdle for MRX1 Cannabidiol Treatment
London-based Ananda Pharma has successfully concluded its Phase 1 pharmacokinetic study for MRX1, confirming a favorable safety profile for the oral cannabidiol solution. With all primary objectives met, the company is now positioning itself to launch Phase 2 clinical trials for endometriosis pain and chemotherapy-induced peripheral neuropathy by mid-2026.
CEO Melissa Sturgess noted that these results validate the company's clinical and regulatory strategy, particularly its FDA 505(b)(2) development pathway. The findings provide the necessary groundwork for the upcoming ENDOCAN and ACTION trials, which are supported by funding from NHS Scotland and the NIHR EME grant respectively. Researchers also evaluated the impact of food on drug absorption, testing a single 2.5 mg/kg dose after a high-fat meal to ensure consistent therapeutic delivery. Having cleared this safety milestone, Ananda Pharma aims to begin patient dosing for its Phase 2 programs in the second half of 2026.
Comments (0)
No comments yet. Be the first!